Oxford Drug Design
The AI engine Fit Assessment
BetaInhibOx leverages advanced machine learning technologies and pattern discovery methods to expand therapeutic options, particularly in the development of novel antibiotics.
Blurb
Oxford Drug Design focuses on developing and delivering services and technologies in computer-aided drug discovery.
HQ Location
Oxford (United Kingdom)
Founded
2001
Employees
1 - 10
Total funding raised
$12.53M
Last Funding Event
Grant, $1.26M, February 20, 2025
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Discovery Optimization
- Drug Repurposing
InhibOx is a pioneer in the development and application of new technologies to drive drug discovery. Their multidisciplinary research team has brought together breakthroughs in computational chemistry, cheminformatics, mathematics, cloud computing and software-as-a-service (SaaS) delivery methods to create DrugFinder: the next generation drug discovery platform.